Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

Supplementary Data 2 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration

<p>DEG Table for R vs NR (mRNAseq)</p>

Saved in:

書目詳細資料
主要作者:	Gregory L. Beatty (15087193) (author)
其他作者:	Devora Delman (15129986) (author), Jiayi Yu (16743347) (author), Mingen Liu (16743350) (author), Joey H. Li (15129989) (author), Liti Zhang (16743353) (author), Jae W. Lee (16743356) (author), Renee B. Chang (15129983) (author), Nathan Bahary (16743359) (author), Eugene P. Kennedy (16743362) (author), Andrea Wang-Gillam (15049923) (author), Gabriela R. Rossi (16743365) (author), Ignacio Garrido-Laguna (15131889) (author)
出版:	2025
主題:	Cancer Therapeutic Research and Development Chemotherapy Gastrointestinal Cancers Pancreatic cancer Translational Research
標簽:	添加標簽沒有標簽, 成為第一個標記此記錄!

相似書籍

Supplementary Data 1 from Treatment Response in First-Line Metastatic Pancreatic Ductal Adenocarcinoma Is Stratified By a Composite Index of Tumor Proliferation and CD8 T-Cell Infiltration
由: Gregory L. Beatty (15087193)
出版: (2025)

Supplementary Data from <i>N</i><sup>6</sup>-methyladenosine Modification of FZR1 mRNA Promotes Gemcitabine Resistance in Pancreatic Cancer
由: Jiachun Su (16990970)
出版: (2025)

Image 9_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
由: Xiangjun Wang (2522917)
出版: (2025)

Image 8_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
由: Xiangjun Wang (2522917)
出版: (2025)

Image 6_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
由: Xiangjun Wang (2522917)
出版: (2025)

Image 7_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
由: Xiangjun Wang (2522917)
出版: (2025)

Image 4_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
由: Xiangjun Wang (2522917)
出版: (2025)

Image 5_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
由: Xiangjun Wang (2522917)
出版: (2025)

Image 3_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
由: Xiangjun Wang (2522917)
出版: (2025)

Image 1_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
由: Xiangjun Wang (2522917)
出版: (2025)

Image 2_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.tif
由: Xiangjun Wang (2522917)
出版: (2025)

Table 3_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
由: Xiangjun Wang (2522917)
出版: (2025)

Table 2_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
由: Xiangjun Wang (2522917)
出版: (2025)

Table 1_Efferocytosis-associated genes serve as prognostic biomarkers for pancreatic ductal adenocarcinoma and identify P2RY6 as a therapeutic target.docx
由: Xiangjun Wang (2522917)
出版: (2025)

Supplementary Table S1 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
由: Erika Y. Faraoni (14844897)
出版: (2025)

Supplementary Table S3 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
由: Erika Y. Faraoni (14844897)
出版: (2025)

Supplementary Table S4 from CD73-Dependent Adenosine Signaling through Adora2b Drives Immunosuppression in Ductal Pancreatic Cancer
由: Erika Y. Faraoni (14844897)
出版: (2025)

Supplementary Figure S1 from First-in-Maintenance Therapy for Localized High-Grade Osteosarcoma: An Open-Label Phase I/II Trial of the Anti–PD-L1 Antibody ZKAB001
由: Yan Zhou (15053225)
出版: (2025)

Supplementary Movie S1 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
由: Fang Wei (15057172)
出版: (2025)

Supplementary Movie S2 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
由: Fang Wei (15057172)
出版: (2025)

Supplementary Movie S3 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
由: Fang Wei (15057172)
出版: (2025)

Supplementary Movie S4 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
由: Fang Wei (15057172)
出版: (2025)

Supplementary Movie S5 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
由: Fang Wei (15057172)
出版: (2025)

Supplementary Movie S6 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
由: Fang Wei (15057172)
出版: (2025)

Supplementary Movie S7 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
由: Fang Wei (15057172)
出版: (2025)

Supplementary Movie S8 from Anticoagulants Enhance Molecular and Cellular Immunotherapy of Cancer by Improving Tumor Microcirculation Structure and Function and Redistributing Tumor Infiltrates
由: Fang Wei (15057172)
出版: (2025)

Supplementary Table S2 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
由: Arun Kanakkanthara (14937731)
出版: (2025)

Supplementary Table S3 from Repurposing Ceritinib Induces DNA Damage and Enhances PARP Inhibitor Responses in High-Grade Serous Ovarian Carcinoma
由: Arun Kanakkanthara (14937731)
出版: (2025)

Figure S1 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Figure S2 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Figure S3 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Figure S4 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Figure S5 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Figure S6 from Combination Therapies Targeting ALK-aberrant Neuroblastoma in Preclinical Models
由: Elizabeth R. Tucker (15053624)
出版: (2025)

Supplementary Figure 1 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Figure 2 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Figure 3 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Figure 4 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Figure 5 from A Phase II Clinical Trial of Nivolumab and Temozolomide for Neuroendocrine Neoplasms
由: Dwight H. Owen (15034782)
出版: (2025)

Supplementary Table 1 from Comprehensive DNA Methylation Analysis Indicates That Pancreatic Intraepithelial Neoplasia Lesions Are Acinar-Derived and Epigenetically Primed for Carcinogenesis
由: Emily K.W. Lo (15618846)
出版: (2025)

Cannot write session to /tmp/vufind_sessions/sess_mgdhrkg0b7kdklmr6r4lkd6t7i